Washington University School of Medicine: Glioblastoma trials

The registry lists 20 Glioblastoma studies with Washington University School of Medicine as lead sponsor. 6 are open to participants now and 5 have results posted.

Early Phase 1 2Phase 1 9Phase 2 7No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent GlioblastomasNot yet recruitingNCT07620548Phase 2
• Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1RecruitingNCT07462507Phase 2
• Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent GlioblastomaRecruitingNCT07392957Phase 1/2
• Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed GlioblastomaRecruitingNCT06831526Early Phase 1
• Neurosurgical Neuronavigation Using Resting State MRI and Machine LearningRecruitingNCT05864976
• Sonobiopsy for Noninvasive and Sensitive Detection of GlioblastomaRecruitingNCT05281731Not applicable
• Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated GlioblastomaActive, not recruitingNCT04015700Phase 1Results posted
• Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent GliomasCompletedNCT03532295Phase 2Results posted
• Temozolomide Chronotherapy for High Grade GliomaCompletedNCT02781792Phase 2Results posted
• Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT02715609Phase 1/2Results posted
• Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain TumorsTerminatedNCT02372409Phase 2Results posted
• Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaActive, not recruitingNCT05743595Phase 1
• Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV AstrocytomaCompletedNCT04757662Phase 1
• Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaTerminatedNCT03422094Phase 1
• Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed GlioblastomaTerminatedNCT02510950Phase 1
• Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS TumorsCompletedNCT01999270Phase 1
• Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With TemozolomideCompletedNCT01907165Early Phase 1
• Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With GlioblastomaCompletedNCT01880008
• MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT01851733Phase 1
• BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain TumorCompletedNCT01124461